Company
Headquarters: Menlo Park, CA, United States
Employees: 133
CEO: Mr. Robert Kelley MBA
$2.7 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Abbott | $233.33 B |
| Boston Scientific Corporation | $154.34 B |
| Stryker | $151.06 B |
| Medtronic | $113.25 B |
| Edwards Lifesciences Corporation | $45.05 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Talis Biomedical Corp has the following listings and related stock indices.
Stock: NASDAQ: TLIS wb_incandescent